Interim analysis of the use of the anti-idiotype breast cancer vaccine 11D10 (TriAb®) in conjunction with autologous stem cell transplantation in patients with metastatic breast cancer

Donna E. Reece; Kenneth A. Foon; Malaya Battacharya-Chatterjee; Doug Adkins; E. Randolph Broun; D. Gerald Connaghan; John F. Dipersio; H. Kent Holland; Dianna S. Howard; Greg A. Hale; Hans G. Klingemann; Rita K. Munn; Anastasios Raptis; Gordon L. Phillips

doi:10.3816/CBC.2001.n.011

Interim analysis of the use of the anti-idiotype breast cancer vaccine 11D10 (TriAb®) in conjunction with autologous stem cell transplantation in patients with metastatic breast cancer

Donna E. Reece, Kenneth A. Foon, Malaya Battacharya-Chatterjee, Doug Adkins, E. Randolph Broun, D. Gerald Connaghan, John F. Dipersio, H. Kent Holland, Dianna S. Howard, Greg A. Hale, Hans G. Klingemann, Rita K. Munn, Anastasios Raptis, Gordon L. Phillips

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

The anti-idiotype monoclonal antibody breast cancer vaccine 11D10 (TriAb®) was administered before and after autologous stem cell transplantation (ASCT) in 45 patients with metastatic breast cancer whose disease was responsive to conventional chemotherapy. Evidence of a positive anti-anti-idiotype antibody (Ab3) humoral response was noted at a median of 1.75 months post-ASCT (range, before ASCT-6 months) with this strategy. Maximal Ab3 levels and idiotype-specific T-cell proliferative responses were observed at a median of 3 and 4 months, respectively, after ASCT. The achievement of rapid immune responses after ASCT, during a known period of decreased immunoresponsiveness, opens the possibility of an additional antitumor effect at a time when the tumor burden is relatively small. Moreover, in this interim analysis, patients with the most vigorous humoral and cellular immune responses had a significant improvement in progression-free survival. Further follow-up and evaluation of this approach is warranted.

Original language	English
Pages (from-to)	52-58
Number of pages	7
Journal	Clinical breast cancer
Volume	2
Issue number	1
DOIs	https://doi.org/10.3816/CBC.2001.n.011
State	Published - Apr 2001

Keywords

Autotransplantation
Human milk fat globule
T-cell proliferative response
TriAb breast cancer vaccine

Access to Document

10.3816/CBC.2001.n.011

Cite this

Reece, D. E., Foon, K. A., Battacharya-Chatterjee, M., Adkins, D., Broun, E. R., Connaghan, D. G., Dipersio, J. F., Holland, H. K., Howard, D. S., Hale, G. A., Klingemann, H. G., Munn, R. K., Raptis, A., & Phillips, G. L. (2001). Interim analysis of the use of the anti-idiotype breast cancer vaccine 11D10 (TriAb®) in conjunction with autologous stem cell transplantation in patients with metastatic breast cancer. Clinical breast cancer, 2(1), 52-58. https://doi.org/10.3816/CBC.2001.n.011

@article{32f75c708a774d2c80148cf00444737c,

title = "Interim analysis of the use of the anti-idiotype breast cancer vaccine 11D10 (TriAb{\textregistered}) in conjunction with autologous stem cell transplantation in patients with metastatic breast cancer",

abstract = "The anti-idiotype monoclonal antibody breast cancer vaccine 11D10 (TriAb{\textregistered}) was administered before and after autologous stem cell transplantation (ASCT) in 45 patients with metastatic breast cancer whose disease was responsive to conventional chemotherapy. Evidence of a positive anti-anti-idiotype antibody (Ab3) humoral response was noted at a median of 1.75 months post-ASCT (range, before ASCT-6 months) with this strategy. Maximal Ab3 levels and idiotype-specific T-cell proliferative responses were observed at a median of 3 and 4 months, respectively, after ASCT. The achievement of rapid immune responses after ASCT, during a known period of decreased immunoresponsiveness, opens the possibility of an additional antitumor effect at a time when the tumor burden is relatively small. Moreover, in this interim analysis, patients with the most vigorous humoral and cellular immune responses had a significant improvement in progression-free survival. Further follow-up and evaluation of this approach is warranted.",

keywords = "Autotransplantation, Human milk fat globule, T-cell proliferative response, TriAb breast cancer vaccine",

author = "Reece, {Donna E.} and Foon, {Kenneth A.} and Malaya Battacharya-Chatterjee and Doug Adkins and Broun, {E. Randolph} and Connaghan, {D. Gerald} and Dipersio, {John F.} and Holland, {H. Kent} and Howard, {Dianna S.} and Hale, {Greg A.} and Klingemann, {Hans G.} and Munn, {Rita K.} and Anastasios Raptis and Phillips, {Gordon L.}",

note = "Funding Information: This study was supported by Amgen, Inc. and Titan Pharmaceuticals, Inc.",

year = "2001",

month = apr,

doi = "10.3816/CBC.2001.n.011",

language = "English",

volume = "2",

pages = "52--58",

journal = "Clinical breast cancer",

issn = "1526-8209",

number = "1",

}

Reece, DE, Foon, KA, Battacharya-Chatterjee, M, Adkins, D, Broun, ER, Connaghan, DG, Dipersio, JF, Holland, HK, Howard, DS, Hale, GA, Klingemann, HG, Munn, RK, Raptis, A & Phillips, GL 2001, 'Interim analysis of the use of the anti-idiotype breast cancer vaccine 11D10 (TriAb®) in conjunction with autologous stem cell transplantation in patients with metastatic breast cancer', Clinical breast cancer, vol. 2, no. 1, pp. 52-58. https://doi.org/10.3816/CBC.2001.n.011

Interim analysis of the use of the anti-idiotype breast cancer vaccine 11D10 (TriAb®) in conjunction with autologous stem cell transplantation in patients with metastatic breast cancer. / Reece, Donna E.; Foon, Kenneth A.; Battacharya-Chatterjee, Malaya et al.
In: Clinical breast cancer, Vol. 2, No. 1, 04.2001, p. 52-58.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Interim analysis of the use of the anti-idiotype breast cancer vaccine 11D10 (TriAb®) in conjunction with autologous stem cell transplantation in patients with metastatic breast cancer

AU - Reece, Donna E.

AU - Foon, Kenneth A.

AU - Battacharya-Chatterjee, Malaya

AU - Adkins, Doug

AU - Broun, E. Randolph

AU - Connaghan, D. Gerald

AU - Dipersio, John F.

AU - Holland, H. Kent

AU - Howard, Dianna S.

AU - Hale, Greg A.

AU - Klingemann, Hans G.

AU - Munn, Rita K.

AU - Raptis, Anastasios

AU - Phillips, Gordon L.

N1 - Funding Information: This study was supported by Amgen, Inc. and Titan Pharmaceuticals, Inc.

PY - 2001/4

Y1 - 2001/4

N2 - The anti-idiotype monoclonal antibody breast cancer vaccine 11D10 (TriAb®) was administered before and after autologous stem cell transplantation (ASCT) in 45 patients with metastatic breast cancer whose disease was responsive to conventional chemotherapy. Evidence of a positive anti-anti-idiotype antibody (Ab3) humoral response was noted at a median of 1.75 months post-ASCT (range, before ASCT-6 months) with this strategy. Maximal Ab3 levels and idiotype-specific T-cell proliferative responses were observed at a median of 3 and 4 months, respectively, after ASCT. The achievement of rapid immune responses after ASCT, during a known period of decreased immunoresponsiveness, opens the possibility of an additional antitumor effect at a time when the tumor burden is relatively small. Moreover, in this interim analysis, patients with the most vigorous humoral and cellular immune responses had a significant improvement in progression-free survival. Further follow-up and evaluation of this approach is warranted.

AB - The anti-idiotype monoclonal antibody breast cancer vaccine 11D10 (TriAb®) was administered before and after autologous stem cell transplantation (ASCT) in 45 patients with metastatic breast cancer whose disease was responsive to conventional chemotherapy. Evidence of a positive anti-anti-idiotype antibody (Ab3) humoral response was noted at a median of 1.75 months post-ASCT (range, before ASCT-6 months) with this strategy. Maximal Ab3 levels and idiotype-specific T-cell proliferative responses were observed at a median of 3 and 4 months, respectively, after ASCT. The achievement of rapid immune responses after ASCT, during a known period of decreased immunoresponsiveness, opens the possibility of an additional antitumor effect at a time when the tumor burden is relatively small. Moreover, in this interim analysis, patients with the most vigorous humoral and cellular immune responses had a significant improvement in progression-free survival. Further follow-up and evaluation of this approach is warranted.

KW - Autotransplantation

KW - Human milk fat globule

KW - T-cell proliferative response

KW - TriAb breast cancer vaccine

UR - http://www.scopus.com/inward/record.url?scp=0035022463&partnerID=8YFLogxK

U2 - 10.3816/CBC.2001.n.011

DO - 10.3816/CBC.2001.n.011

M3 - Article

C2 - 11899383

AN - SCOPUS:0035022463

SN - 1526-8209

VL - 2

SP - 52

EP - 58

JO - Clinical breast cancer

JF - Clinical breast cancer

IS - 1

ER -

Interim analysis of the use of the anti-idiotype breast cancer vaccine 11D10 (TriAb®) in conjunction with autologous stem cell transplantation in patients with metastatic breast cancer

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this